Skip to main content
. 2021 Dec 14;3(1):100486. doi: 10.1016/j.xcrm.2021.100486

Figure 2.

Figure 2

Serum neutralization of SARS-CoV-2 pseudovirus

(A) Post-infection serum neutralization levels to SARS-CoV-2. The posterior 2-phase median decay slope and its 95% credible interval are plotted as black and gray lines, respectively. The posterior median transition time point between the 2 phases is indicated as a dashed vertical line.

(B) Pre- (week 0 = before first dose, n = 150 participants), post-vaccination (week 4 = before second dose, n = 101 participants), and HCW control (n = 49) distributions of SARS-CoV-2 pseudovirus neutralization.

(C) Pre-vaccination (week 0, n = 30 participants) and post-vaccination (week 1, n = 30 participants, and week 8, n = 21 participants) serum neutralization distributions of WT D614G and VOC lineages Alpha, Beta, Gamma, and Delta. Each point represents 1 participant colored by COVID-19 severity.

∗: distributions with non-overlapping 95% CI of group mean effect size estimated using a Bayesian ANOVA model (Table S4). Median with interquartile range is depicted. Areas of neutralization titers below detection limit are shaded in gray.